Drugs / Jaktinib
Jaktinib
also known as
Jaktinib Hydrochloride Tablets · gecacitinib · Jaktinib hydrochloride · Jaktinib Hydrochloride Tablet
targets JAK2 via inhibition
Trials 30
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-12-07 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Results 2024 ASH I 泽璟制药盐酸吉卡昔替尼片研究成果亮相 zelgen.com ↗ |
| 2024-05-06 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Regulatory 泽璟制药“盐酸杰克替尼”通用名称核定为“盐酸吉卡昔替尼”的提示 zelgen.com ↗ |
| 2023-06-13 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Results 泽璟制药盐酸杰克替尼片III期临床数据亮相2023EHA 带来骨髓纤维化患者治疗新选择 zelgen.com ↗ |
| 2023-05-16 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Results EHA 2023 口头报告 I 泽璟制药盐酸杰克替尼片关键临床研究成果重磅公布 zelgen.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-07 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024 ASH I 泽璟制药盐酸吉卡昔替尼片研究成果亮相 zelgen.com ↗ |
| 2024-05-06 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 泽璟制药“盐酸杰克替尼”通用名称核定为“盐酸吉卡昔替尼”的提示 zelgen.com ↗ |
| 2023-06-13 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 泽璟制药盐酸杰克替尼片III期临床数据亮相2023EHA 带来骨髓纤维化患者治疗新选择 zelgen.com ↗ |
| 2023-05-16 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | EHA 2023 口头报告 I 泽璟制药盐酸杰克替尼片关键临床研究成果重磅公布 zelgen.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Jaktinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03314402 ↗ |
| Known as | gecacitinib | “To compare the efficacy and safety of gecacitinib (also known as jaktinib) with hydroxyurea (HU) in treating myelofibrosis (MF) patients.” PMID 39695117 ↗ Dec 2024 |
| Known as | Jaktinib hydrochloride | “Jaktinib hydrochloride tablets, 2 x 50mg dosage, BID” NCT05686629 ↗ |
| Known as | Jaktinib Hydrochloride Tablet | “Drug: Jaktinib Hydrochloride Tablet 100mg dosage, orally administered, twice a day” NCT05676242 ↗ |
| Known as | Jaktinib Hydrochloride Tablets | “A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Adult Patients With Moderate and...” NCT05526222 ↗3“jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis” NCT05676242 ↗ “Jaktinib hydrochloride tablets, 2 x 50mg dosage, BID” NCT05688839 ↗ “Drug: Jaktinib hydrochloride tablets” NCT05702788 ↗ |
| Action | Inhibit | “oral JAK2 Inhibitor” NCT03314402 ↗ |
| Route | Oral | “an Oral JAK2 Inhibitor” NCT03314402 ↗ |
| Target | JAK2 | “oral JAK2 Inhibitor” NCT03314402 ↗ |